Tadaaki Nishikawa

19PUBLICATIONS
84CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedNutritional epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 01, 2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

Shin Nishio, Tadaaki Nishikawa, Masahiko Mori

|Jun 23, 2025
Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models.

Shigehiro Yagishita, Sho Sato, Daisuke Shintani

|Mar 12, 2025
Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.

Taro Yamanaka, Tadaaki Nishikawa, Hiroshi Yoshida

|Aug 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Rui Kitadai, Tatsunori Shimoi, Shu Yazaki

|Jul 30, 2024
Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).

Tadaaki Nishikawa, Shigeki Kakunaga, Kenji Tamura

|Jul 11, 2024
HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma.

Chiharu Mizoguchi, Tadaaki Nishikawa, Hiroshi Yoshida

Pageof 4

Frequent Collaborators

9 joint publications

Hiroshi Yoshida

9 joint publications

Kan Yonemori

5 joint publications

Kosei Hasegawa

5 joint publications

Tomoyasu Kato